| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | 1 | Y | 0 CD19 CAR T-cell Therapy | 396 | 246 | 93 | 52 | 17 | 5 | 0 | 06/12/2023 | 137 | 44 |
| 246 | 93 | 52 | 17 | 5 | 0 | |||||||||
| 2 | Y | 1 Mosunetuzumab | 14 | 5 | 4 | 2 | 1 | 0 | 06/12/2023 | |||||
| 2 Polatuzumab | 12 | 4 | 1 | 0 | 0 | 0 | ||||||||
| 3 Mosunetuzumab + Polatuzumab | 13 | 5 | 3 | 2 | 0 | 0 | ||||||||
| 4 Observation | 14 | 6 | 4 | 3 | 0 | 0 | ||||||||
| 53 | 20 | 12 | 7 | 1 | 0 | |||||||||
| 3 | Y | 5 Mosunetuzumab + Polatuzumab | 4 | 1 | 0 | 0 | 0 | 0 | 06/12/2023 | |||||
| 4 | 1 | 0 | 0 | 0 | 0 | |||||||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | 1 | Y | 1 Tazemetostat (Arm 1) Dose Level 1 | 173 | 7 | 0 | 0 | 0 | 0 | 0 | 09/26/2023 | 141 | 40 | |
| 10 Tazemetostat (Arm 1) Dose Level 1 | 6 | 4 | 0 | 0 | 0 | 0 | ||||||||
| 11 Tazemetostat (Arm 1) Dose Level 2 | 5 | 5 | 0 | 0 | 0 | 0 | ||||||||
| 13 Zanubrutinib (Arm 3) Dose Level 2 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||||
| 4 Zanubrutinib (Arm 3) Dose Level 1 | 10 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 5 Zanubrutinib (Arm 3) Dose Level 2 | 10 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 9 Tafasitamab + Lenalidomide + Zanubrutinib | 1 | 1 | 1 | 1 | 1 | 0 | ||||||||
| 40 | 11 | 1 | 1 | 1 | 0 | |||||||||
| S2308-FL, LTB, Mosunetuzumab vs Rituximab | 1 | Y | 1 Rituximab | 600 | 205 | 121 | 69 | 26 | 7 | 1 | 10/23/2024 | 260 | 91 | |
| 2 Mosunetuzumab | 209 | 125 | 75 | 34 | 11 | 4 | ||||||||
| 414 | 246 | 144 | 60 | 18 | 5 | |||||||||
| Yes | A051902-PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P | 1 | E | Total Registrations | 19 | 0 | 0 | 0 | 0 | 0 | 10/14/2023 | 224 | 80 | |
| 19 | 0 | 0 | 0 | 0 | 0 | |||||||||
| A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub | 1 | E | Total Registrations | 37 | 17 | 6 | 3 | 2 | 0 | 01/03/2024 | 236 | 78 | ||
| 37 | 17 | 6 | 3 | 2 | 0 | |||||||||
| 2 | E | Total Registrations | 18 | 7 | 4 | 4 | 2 | 0 | 01/03/2024 | |||||
| 18 | 7 | 4 | 4 | 2 | 0 | |||||||||
| AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy | 1 | E | Total Registrations | 114 | 48 | 24 | 12 | 3 | 0 | 08/15/2023 | 367 | 133 | ||
| 114 | 48 | 24 | 12 | 3 | 0 | |||||||||
| 2 | E | Total Registrations | 105 | 46 | 26 | 14 | 6 | 0 | 08/15/2023 | |||||
| 105 | 46 | 26 | 14 | 6 | 0 | |||||||||
| No | A042302-CLL/SLL, Untreated Older, Zan+Son | 0 | E | Total Registrations | 12 | 12 | 12 | 12 | 2 | 0 | 06/22/2026 | 26 | 6 | |
| 12 | 12 | 12 | 12 | 2 | 0 | |||||||||
| 1 | E | Total Registrations | 11 | 11 | 11 | 11 | 3 | 0 | 06/22/2026 | |||||
| 11 | 11 | 11 | 11 | 3 | 0 | |||||||||
| EA4231-Lymph, DL B-Cell, Ven+Ib+Pred+Ob+Rev | 1 | E | Total Registrations | 1 | 1 | 1 | 0 | 0 | 0 | 03/30/2026 | 35 | 9 | ||
| 1 | 1 | 1 | 0 | 0 | 0 | |||||||||
| EA4232-Lymph, Peri T Cell, Auto Stem | 1 | E | Total Registrations | 2 | 2 | 0 | 0 | 0 | 0 | 09/15/2025 | 123 | 36 | ||
| 2 | 2 | 0 | 0 | 0 | 0 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| S2506 NHL, R/R MZL, Mozun +/- Zanu or Pola | 1 Randomization | 18-Aug-26 | 5 | 3 |
| A042302 CLL/SLL, Untreated Older, Zan+Son | 2 Randomization | 06-Mar-26 | 26 | 6 |